Metropolitan Life Insurance CO Tango Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.76 - $8.06 $3,090 - $6,625	-822 Reduced 24.86%	2,484 $9,000
Q4 2022 Jun 14, 2023	BUY	$3.41 - $8.29 $2,803 - $6,814	822 Added 33.09%	3,306 $24 Million
Q4 2022 Mar 30, 2023	SELL	$3.41 - $8.29 $61 - $149	-18 Reduced 0.54%	3,306 $23,000
Q4 2022 Feb 15, 2023	BUY	$3.41 - $8.29 $11,273 - $27,406	3,306 New	3,306 $23,000
Q2 2022 Jun 20, 2023	BUY	$3.86 - $8.01 $3,242 - $6,728	840 Added 33.82%	3,324 $15,000
Q2 2022 Mar 30, 2023	BUY	$3.86 - $8.01 $69 - $144	18 Added 0.54%	3,324 $15,000
Q2 2022 Aug 11, 2022	BUY	$3.86 - $8.01 $12,830 - $26,625	3,324 New	3,324 $15,000

123

91.7M

3.1K

1.5K

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $359M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.